Alpha 2.0
Login Register
» Authors » Bianca Maria Longo

Bianca Maria Longo

Explore the profile of Bianca Maria Longo including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 7
Citations 57
Followers 0
Related Specialties
Pharmacology
Microbiology
Public Health
Top 10 Co-Authors
Andrea Calcagno
Stefano Bonora
Francesco Venuti
Mattia Trunfio
Giovanni Di Perri
Francesca Alladio
Fabio Antonino Ranzani
Francesco Giuseppe De Rosa
Francesco Cerutti
Alberto Gaviraghi
Published In
Antibiotics (Basel)
Viruses
Trop Med Int Health
Front Microbiol
J Glob Antimicrob Resist
Affiliations
Soon will be listed here.
Recent Articles
1.
Dual β-lactams for the treatment of Mycobacterium abscessus: a review of the evidence and a call to act against an antibiotic nightmare
Longo B, Trunfio M, Calcagno A
J Antimicrob Chemother . 2024 Aug; 79(11):2731-2741. PMID: 39150384
Mycobacterium abscessus complex is a group of rapidly growing non-tuberculous mycobacteria (NTM), increasingly emerging as opportunistic pathogens. Current treatment options for these microorganisms are limited and associated with a high...
2.
Risk factors for mortality in Acinetobacter baumannii bloodstream infections and development of a predictive mortality model
Corcione S, Longo B, Scabini S, Pivetta E, Curtoni A, Shbaklo N, et al.
J Glob Antimicrob Resist . 2024 Jul; 38:317-326. PMID: 39029658
Objectives: Acinetobacter baumannii (A. baumannii) nosocomial infections represent a serious hazard to public health, given high mortality rates and rapid spread of multidrug-resistance. The primary outcome of this study was...
3.
A noma case report: A warning message from Northern Uganda
Longo B, Merli M, Achana B, Okao M, Okot G, Ribero S, et al.
Trop Med Int Health . 2024 Jul; 29(8):752-755. PMID: 38946064
Noma, or Cancrum oris, is a severe and rapidly progressing gangrenous infection that primarily affects the face. It is most commonly observed in children living in impoverished conditions, especially in...
4.
Sequential or Combination Treatments as Rescue Therapies in Immunocompromised Patients with Persistent SARS-CoV-2 Infection in the Omicron Era: A Case Series
Longo B, Venuti F, Gaviraghi A, Lupia T, Ranzani F, Pepe A, et al.
Antibiotics (Basel) . 2023 Sep; 12(9). PMID: 37760757
Prolonged SARS-CoV-2 infections are widely described in immunosuppressed patients, but safe and effective treatment strategies are lacking. We aimed to outline our approach to treating persistent COVID-19 in patients with...
5.
Real-Life Experience of Continuously Infused Ceftolozane/Tazobactam in Patients with Bronchiectasis and Multidrug-Resistant Infection in the Outpatient Setting
Venuti F, Gaviraghi A, De Nicolo A, Stroffolini G, Longo B, Di Vincenzo A, et al.
Antibiotics (Basel) . 2023 Jul; 12(7). PMID: 37508309
(1) Background: Ceftolozane/tazobactam (C/T) is a novel β-lactam/β-lactamase inhibitor with excellent activity against the multidrug-resistant (MDR) . Continuous infusion (CI) dosing allows the optimization of pharmacokinetic and pharmacodynamic (PK/PD) properties...
6.
On the SARS-CoV-2 "Variolation Hypothesis": No Association Between Viral Load of Index Cases and COVID-19 Severity of Secondary Cases
Trunfio M, Longo B, Alladio F, Venuti F, Cerutti F, Ghisetti V, et al.
Front Microbiol . 2021 Apr; 12:646679. PMID: 33815334
Emerging evidence supports the "variolation hypothesis" in severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), but the derivative idea that the viral load of index cases may predict disease severity in secondary...
7.
Diagnostic SARS-CoV-2 Cycle Threshold Value Predicts Disease Severity, Survival, and Six-Month Sequelae in COVID-19 Symptomatic Patients
Trunfio M, Venuti F, Alladio F, Longo B, Burdino E, Cerutti F, et al.
Viruses . 2021 Mar; 13(2). PMID: 33670360
To date, there is no severe acute respiratory syndrome coronavirus 2-(SARS-CoV-2)-specific prognostic biomarker available. We assessed whether SARS-CoV-2 cycle threshold (Ct) value at diagnosis could predict novel CoronaVirus Disease 2019...